Abstract Background Ansofaxine (LY03005) extended-release tablet is a potential triple
reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the …

Major depressive disorder (MDD) is the most prevalent form of depression and is becoming
a great challenge for public health and medical practice. Although first-line antidepressants …

The estimated rate of treatment-resistant major depressive disorder (TRD) remains higher
than 30%, even after the discovery of multiple classes of antidepressants in the last 7 …

Purpose The purpose of this study is to investigate the efficacy, safety, and tolerability of
agomelatine and paroxetine in Chinese Han patients with major depressive disorder (MDD) …

Background Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated
antidepressant effects in a previous exploratory study in patients with major depressive …

Purpose/Background: Centanafadine is an inhibitor of norepinephrine, dopamine, and
serotonin reuptake transporters under investigation for the treatment of attention …

Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA
receptors, possesses anxiolytic‐like actions at doses devoid of the side effects typically …

Objective: To examine the efficacy and safety of adjunctive armodafinil for major depressive
episodes associated with bipolar I disorder. Method: Adults meeting DSM-IV-TR criteria for …

Background In a previous study, adjunctive armodafinil 150 mg/day significantly improved
depressive symptoms associated with bipolar I disorder. Methods Multicenter, double-blind …

Method. In this small, open-label trial of acamprosate, we treated 21 patients with a clinical
DSM-IV diagnosis of an anxiety disorder, including panic disorder, generalized anxiety …